Dynavax Technologies Corporation

Dynavax Technologies Corporation is a biopharmaceutical company that specializes in developing and commercializing vaccines to prevent infectious diseases and provide immunotherapy for cancer. The primary function of Dynavax is to leverage its advanced technologies in immunology to create innovative solutions that enhance immune responses. Notably, the company has developed HEPLISAV-B, an FDA-approved hepatitis B vaccine for adults, which stands out due to its two-dose regimen completed in one month, offering a faster and potentially more effective vaccination compared to traditional three-dose hepatitis B vaccines. Dynavax's work also extends to adjuvant technologies, including CpG 1018, which is used to improve the efficacy of vaccines. Predominantly impacting the healthcare sector, Dynavax's products and technologies contribute significantly to public health by addressing unmet needs in infectious disease prevention. Headquartered in Emeryville, California, Dynavax plays a crucial role in the biopharmaceutical industry, striving to enhance vaccine performance and accessibility while responding to global health challenges.